SOPHiA GENETICS SA (SOPH)
NASDAQ: SOPH · Real-Time Price · USD
3.295
+0.035 (1.07%)
Mar 31, 2025, 2:24 PM EDT - Market open

Company Description

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space.

The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities.

Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.

SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

SOPHiA GENETICS SA
SOPHiA GENETICS logo
Country Switzerland
Founded 2011
IPO Date Jul 23, 2021
Industry Health Information Services
Sector Healthcare
Employees 423
CEO Jurgi Camblong

Contact Details

Address:
La PiEce 12
Rolle, 1180
Switzerland
Phone 41 21 694 10 60
Website sophiagenetics.com

Stock Details

Ticker Symbol SOPH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001840706
CUSIP Number H82027105
ISIN Number CH1125843347
SIC Code 7374

Key Executives

Name Position
Dr. Jurgi Camblong M.B.A., Ph.D. Co-Founder, Chief Executive Officer and Director
Ross Jordan Muken B.Sc. President
George A. Cardoza M.B.A. Executive Vice President and Chief Financial Officer
Abhimanyu Verma Senior Vice President and Chief Technology Officer
Dr. Zhenyu Xu Ph.D. Executive Vice President and Chief Scientific Officer
Kellen Sanger Head of Strategy and Investor Relations
Daan van Well L.L.M., M.B.A. Executive Vice President, Chief Legal and Regulatory Officer
Manuela Da Silva Valente B.A. Executive Vice President and Chief People Officer
Kevin Puylaert Vice President and MD of EMEA
Dr. Philippe Menu M.B.A., M.D., Ph.D. Executive Vice President, Chief Medical Officer and Chief Product Officer

Latest SEC Filings

Date Type Title
Mar 24, 2025 144 Filing
Mar 24, 2025 144 Filing
Mar 24, 2025 144 Filing
Mar 19, 2025 144 Filing
Mar 4, 2025 20-F Annual and transition report of foreign private issuers
Mar 4, 2025 6-K Report of foreign issuer
Feb 19, 2025 144 Filing
Feb 19, 2025 144 Filing
Jan 27, 2025 144 Filing
Jan 27, 2025 144 Filing